Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Junctional adhesion molecule 2 (JAM2)
- Target
- JAM2
- Molecular classification
- Immunoglobulin superfamily member, Type I membrane protein, Cell adhesion molecule (CAM)
01
Overview
Junctional adhesion molecule 2 (JAM2) is a cell surface protein of the immunoglobulin superfamily, primarily located at tight junctions of endothelial and epithelial cells. JAM2 mediates cell-cell adhesion through homophilic and heterophilic interactions, notably with JAM3 and integrins (particularly α4β1), controlling paracellular permeability, leukocyte transmigration, cell polarity, and vascular integrity. It is critical in immune responses, stem cell homing, spermatogenesis, and myogenesis. Alterations in JAM2 are associated with various pathologies, such as cancer, inflammatory and autoimmune diseases, and vascular disorders. JAM2 is used as a prognostic biomarker in certain cancers and can be detected in tissue and plasma via immunoassays. Therapeutic targeting is challenging due to its essential physiological roles and wide tissue distribution[1][2][4][5][7].
- Other names
- JAM-BJAMBCD322C21orf43VE-JAMPRO245IBGC8Vascular endothelial junction-associated moleculeJunctional adhesion molecule B
02
Mechanism of action
null
03
Biological functions
Cell-cell adhesionTight junction formation and maintenance (epithelial and endothelial cells)Leukocyte transmigration and extravasation (interacts with integrins, mediates immune cell migration)Cell polarity regulationHematopoietic stem cell homing/retentionSpermatogenesis (germ cell anchorage and Sertoli cell interaction)Regulation of vascular permeability and integrityCell motility and proliferation
04
Disease associations
Cancer (inhibits proliferation, metastasis, and epithelial-mesenchymal transition in lung adenocarcinoma)Inflammation (regulates leukocyte migration; implicated in chronic inflammatory diseases)Cardiovascular disease (vascular dysfunction, integrity, and permeability issues)Autoimmune disease (immune cell trafficking and tissue infiltration)Brain calcification disorders (e.g., basal ganglia calcification syndromes)
05
Safety considerations
Targeting JAM2 may affect immune cell recruitment (risk of immunosuppression or exacerbating inflammation depending on modulation)Potential for impact on vascular barrier integrity (leading to edema or vascular leakage)Possible reproductive consequences (role in germ cell-Sertoli cell interactions)Challenges in specificity (broad expression in various vital tissues)
06
Biomarkers
Prognostic biomarker in lung adenocarcinomaBlood and tissue testing kits available for JAM2 detection (ELISA, CLIA kits)
Beyond the preview
Go deeper on Junctional adhesion molecule 2 (JAM2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Junctional adhesion molecule 2 (JAM2).